By early 2026, FDA had publicly announced enforcement actions against multiple compounded GLP-1 telehealth platforms, and in April 2026 formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list - with a public comment period running through June 2026
However, rapid weight loss itself is a known risk factor for developing gallstones, which are a leading cause of pancreatitis
The most common are nausea, vomiting, and diarrhea
Some of those taking the drug, however, shed as much as 20% of their starting weight
Dysbiosis impairs incretin signaling, reducing the effectiveness of GLP-1 therapies
Overall, the inclusion of semaglutide GLP-1 in our treatment offerings positions Arden Creek Laser and Aesthetics at the forefront of weight management solutions, providing patients with a potent option that addresses both weight and metabolic parameters